Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis

Neuropharmacology

Volumn 110, Issue , 2016, Pages 644-653

  Sedel, Frédéric ^a   Bernard, Delphine ^a   Mock, Donald M ^b   Tourbah, Ayman ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c REIMS UNIVERSITY HOSPITAL   (France)

Author keywords

Biotin; Multiple sclerosis; Promyelinogenic agent; Virtual hypoxia

Indexed keywords

BIOTIN; CARBOXYLASE; CENTRAL NERVOUS SYSTEM AGENTS; IDEBENONE; MD 1003; MYELIN; UNCLASSIFIED DRUG; VITAMIN B COMPLEX;

AXON; AXONAL INJURY; BRAIN CHEMISTRY; CELL HYPOXIA; CELL LOSS; CONTROLLED CLINICAL TRIAL (TOPIC); DEMYELINATION; DISEASE COURSE; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENERGY YIELD; FATTY ACID SYNTHESIS; FEASIBILITY STUDY; HUMAN; HYPOXIA; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; MYELIN SHEATH; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; OLIGODENDROGLIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMYELINIZATION; REVIEW; SIDE EFFECT; TERATOGENICITY; VIRTUAL HYPOXIA; ANIMAL; COMPLICATION; DEMYELINATING DISEASES; PATHOPHYSIOLOGY;

ANIMALS; BIOTIN; DEMYELINATING DISEASES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPOXIA; MULTIPLE SCLEROSIS; VITAMIN B COMPLEX;

EID: 84992755490     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2015.08.028     Document Type: Review

References (139)

1. Arnold, D.L., Matthews, P.M., Francis, G.S., O'Connor, J., Antel, J.P., Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann. Neurol. 31 (1992), 235–241.
2. Bai, L., Lennon, D.P., Caplan, A.I., DeChant, A., Hecker, J., Kranso, J., Zaremba, A., Miller, R.H., Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nat. Neurosci. 15 (2012), 862–870.
3. Ballhausen, D., Mittaz, L., Boulat, O., Bonafe, L., Braissant, O., Evidence for catabolic pathway of propionate metabolism in CNS: expression pattern of methylmalonyl-CoA mutase and propionyl-CoA carboxylase alpha-subunit in developing and adult rat brain. Neuroscience 164 (2009), 578–587.
4. Bindu, P.S., Noone, M.L., Nalini, A., Muthane, U.B., Kovoor, J.M., Biotin-responsive basal ganglia disease: a treatable and reversible neurological disorder of childhood. J. Child Neurol. 24 (2009), 750–752.
5. Biogen Idec Ltd, Tysabri (Natalizumab) Summary of Product Characteristics. 2011 Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000603/human_med_001119.jsp&mid=WC0b01ac058001d124 (accessed 01.12.14.).
6. Biogen Idec Ltd, Avonex (Interferon Beta-1a) Summary of Product Characteristics. 2014 Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002202/human_med_001433.jsp&mid=WC0b01ac058001d124 (accessed 01.12.14.).
7. Bitsch, A., Schuchardt, J., Bunkowski, S., Kuhlmann, T., Bruck, W., Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 123 (2000), 1174–1183.
8. Bjartmar, C., Kidd, G., Mork, S., Rudick, R., Trapp, B.D., Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann. Neurol. 48 (2000), 893–901.
9. Bjartmar, C., Kinkel, R.P., Kidd, G., Rudick, R.A., Trapp, B.D., Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 57 (2001), 1248–1252.
10. Bjartmar, C., Wujek, J.R., Trapp, B.D., Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J. Neurol. Sci. 206 (2003), 165–171.
11. Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Goelz, S., Natarajan, A., Lee, S., Plavina, T., Scanlon, J.V., Sandrock, A., Bozic, C., Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366 (2012), 1870–1880.
12. Browne, P., Chandraratna, D., Angood, C., Tremlett, H., Baker, C., Taylor, B.V., Thompson, A.J., Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology 83 (2014), 1022–1024.
13. Bruck, W., Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis. J. Neurol. 252 (2005), v10–v15.
14. Brugarolas, P., Popko, B., Remyelination therapy goes to trial for multiple sclerosis. Neurol. Neuroimmunol. Neuroinflammation, 1, 2014, e26.
15. Burt, R.K., Balabanov, R., Han, X., Sharrack, B., Morgan, A., Quigley, K., Yaung, K., Helenowski, I.B., Jovanovic, B., Spahovic, D., Arnautovic, I., Lee, D.C., Benefield, B.C., Futterer, S., Oliveira, M.C., Burman, J., Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. JAMA 313 (2015), 275–284.
16. Cadavid, D., Balcer, L., Galetta, S., Aktas, O., Ziemssen, T., Vanopdenbosch, L., Butzkueven, H., Ziemssen, F., Massacesi, L., Chai, Y., Xu, L., Freeman, S., Efficacy analysis of the anti-LINGO-1 monoclonal antibody BIIB033 in acute optic neuritis: the RENEW trial (P7.202). Neurology, 84, 2015 Poster p7.202.
17. Campbell, G.R., Ziabreva, I., Reeve, A.K., Krishnan, K.J., Reynolds, R., Howell, O., Lassmann, H., Turnbull, D.M., Mahad, D.J., Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann. Neurol. 69 (2011), 481–492.
18. Castle, J.C., Hara, Y., Raymond, C.K., Garrett-Engele, P., Ohwaki, K., Kan, Z., Kusunoki, J., Johnson, J.M., ACC2 is expressed at high levels in human white adipose and has an isoform with a novel N-terminus. PLoS One, 4, 2009, e4369.
19. Chakraborty, G., Ledeen, R., Fatty acid synthesizing enzymes intrinsic to myelin. Brain Res. Mol. Brain Res. 112 (2003), 46–52.
20. Chapman-Smith, A., Cronan, J.E. Jr., The enzymatic biotinylation of proteins: a post-translational modification of exceptional specificity. Trends Biochem. Sci. 24 (1999), 359–363.
21. Chauhan, J., Dakshinamurti, K., Transcriptional regulation of the glucokinase gene by biotin in starved rats. J. Biol. Chem. 266 (1991), 10035–10038.
22. Chen, J.T., Collins, D.L., Atkins, H.L., Freedman, M.S., Arnold, D.L., Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann. Neurol. 63 (2008), 254–262.
23. Chiang, G.S., Mistry, S.P., Activities of pyruvate carboxylase and propionyl CoA carboxylase in rat tissues during biotin deficiency and restoration of the activities after biotin administration. Proc. Soc. Exp. Biol. Med. 146 (1974), 21–24.
24. Coles, A.J., Fox, E., Vladic, A., Gazda, S.K., Brinar, V., Selmaj, K.W., Skoromets, A., Stolyarov, I., Bass, A., Sullivan, H., Margolin, D.H., Lake, S.L., Moran, S., Palmer, J., Smith, M.S., Compston, D.A., Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 78 (2012), 1069–1078.
25. Comi, G., Disease-modifying treatments for progressive multiple sclerosis. Mult. Scler. 19 (2013), 1428–1436.
26. Compston, A., Coles, A., Multiple sclerosis. Lancet 372 (2008), 1502–1517.
27. Confavreux, C., O'Connor, P., Comi, G., Freedman, M.S., Miller, A.E., Olsson, T.P., Wolinsky, J.S., Bagulho, T., Delhay, J.L., Dukovic, D., Truffinet, P., Kappos, L., Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 13 (2014), 247–256.
28. Confavreux, C., Vukusic, S., Natural history of multiple sclerosis: a unifying concept. Brain 129 (2006), 606–616.
29. Confavreux, C., Vukusic, S., Moreau, T., Adeleine, P., Relapses and progression of disability in multiple sclerosis. N. Engl. J. Med. 343 (2000), 1430–1438.
30. Craner, M.J., Newcombe, J., Black, J.A., Hartle, C., Cuzner, M.L., Waxman, S.G., Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 8168–8173.
31. Cuker, A., Coles, A.J., Sullivan, H., Fox, E., Goldberg, M., Oyuela, P., Purvis, A., Beardsley, D.S., Margolin, D.H., A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood 118 (2011), 6299–6305.
32. De Stefano, N., Matthews, P.M., Fu, L., Narayanan, S., Stanley, J., Francis, G.S., Antel, J.P., Arnold, D.L., Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 121 (1998), 1469–1477.
33. De Stefano, N., Narayanan, S., Francis, G.S., Arnaoutelis, R., Tartaglia, M.C., Antel, J.P., Matthews, P.M., Arnold, D.L., Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch. Neurol. 58 (2001), 65–70.
34. Denic, A., Wootla, B., Rodriguez, M., CD8(+) T cells in multiple sclerosis. Expert Opin. Ther. Targets 17 (2013), 1053–1066.
35. Deshmukh, V.A., Tardif, V., Lyssiotis, C.A., Green, C.C., Kerman, B., Kim, H.J., Padmanabhan, K., Swoboda, J.G., Ahmad, I., Kondo, T., Gage, F.H., Theofilopoulos, A.N., Lawson, B.R., Schultz, P.G., Lairson, L.L., A regenerative approach to the treatment of multiple sclerosis. Nature 502 (2013), 327–332.
36. DeWille, J.E., Horrocks, L.A., Synthesis and turnover of myelin phospholipids and cholesterol. Martensson, R.E., (eds.) Myelin: Biology and Chemistry, 1992, CRC Press, Boca Raton, FL, USA.
37. Dokusova, O.K., Krivoruchenko, I.V., The effect of biotin on the level of cholesterol in the blood of patients with atherosclerosis and essential hyperlipidemia. Kardiologiia, 12, 1972, 113.
38. Duncan, I.D., Brower, A., Kondo, Y., Curlee, J.F. Jr., Schultz, R.D., Extensive remyelination of the CNS leads to functional recovery. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 6832–6836.
39. Dutta, R., McDonough, J., Yin, X., Peterson, J., Chang, A., Torres, T., Gudz, T., Macklin, W.B., Lewis, D.A., Fox, R.J., Rudick, R., Mirnics, K., Trapp, B.D., Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann. Neurol. 59 (2006), 478–489.
40. Dutta, R., Trapp, B.D., Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 68 (2007), S22–S31.
41. Dutta, R., Trapp, B.D., Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog. Neurobiol. 93 (2011), 1–12.
42. Fiebiger, S.M., Bros, H., Grobosch, T., Janssen, A., Chanvillard, C., Paul, F., Dorr, J., Millward, J.M., Infante-Duarte, C., The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the mouse. J. Neuroimmunol. 262 (2013), 66–71.
43. Filenko, N.A., Kolar, C., West, J.T., Smith, S.A., Hassan, Y.I., Borgstahl, G.E., Zempleni, J., Lyubchenko, Y.L., The role of histone H4 biotinylation in the structure of nucleosomes. PLoS One, 6, 2011, e16299.
44. Foster, D.W., Malonyl-CoA: the regulator of fatty acid synthesis and oxidation. J. Clin. Invest. 122 (2012), 1958–1959.
45. Franklin, R.J., Ffrench-Constant, C., Remyelination in the CNS: from biology to therapy. Nat. Rev. Neurosci. 9 (2008), 839–855.
46. Gibson, J., Frank, A., Supporting individuals with disabling multiple sclerosis. J. R. Soc. Med. 95 (2002), 580–586.
47. Goldschmidt, T., Antel, J., Konig, F.B., Bruck, W., Kuhlmann, T., Remyelination capacity of the MS brain decreases with disease chronicity. Neurology 72 (2009), 1914–1921.
48. Gralla, M., Camporeale, G., Zempleni, J., Holocarboxylase synthetase regulates expression of biotin transporters by chromatin remodeling events at the SMVT locus. J. Nutr. Biochem. 19 (2008), 400–408.
49. Haefeli, R.H., Erb, M., Gemperli, A.C., Robay, D., Courdier, F.I., Anklin, C., Dallmann, R., Gueven, N., NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels. PLoS One, 6, 2011, e17963.
50. Hassel, B., Carboxylation and anaplerosis in neurons and glia. Mol. Neurobiol. 22 (2000), 21–40.
51. Hathcock, J.N., Vitamin and Mineral Safety. 2015, Council for Responsible Nutrition (CRN), Washington, D.C., USA.
52. Healy, S., Perez-Cadahia, B., Jia, D., McDonald, M.K., Davie, J.R., Gravel, R.A., Biotin is not a natural histone modification. Biochim. Biophys. Acta 1789 (2009), 719–733.
53. Hernandez-Vazquez, A., Ochoa-Ruiz, E., Ibarra-Gonzalez, I., Ortega-Cuellar, D., Salvador-Adriano, A., Velazquez-Arellano, A., Temporal development of genetic and metabolic effects of biotin deprivation. A search for the optimum time to study a vitamin deficiency. Mol. Genet. Metab. 107 (2012), 345–351.
54. Hernandez-Vazquez, A., Wolf, B., Pindolia, K., Ortega-Cuellar, D., Hernandez-Gonzalez, R., Heredia-Antunez, A., Ibarra-Gonzalez, I., Velazquez-Arellano, A., Biotinidase knockout mice show cellular energy deficit and altered carbon metabolism gene expression similar to that of nutritional biotin deprivation: clues for the pathogenesis in the human inherited disorder. Mol. Genet. Metab. 110 (2013), 248–254.
55. IOM Standing Committee on the Scientific Evaluation of Dietary Reference Intervals, Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. 1998, National Academy Press, Washington, DC, USA.
56. Jepson, S., Vought, B., Gross, C.H., Gan, L., Austen, D., Frantz, J.D., Zwahlen, J., Lowe, D., Markland, W., Krauss, R., LINGO-1, a transmembrane signaling protein, inhibits oligodendrocyte differentiation and myelination through intercellular self-interactions. J. Biol. Chem. 287 (2012), 22184–22195.
57. Kappos, L., Radue, E.W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., Burtin, P., A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362 (2010), 387–401.
58. Kingwell, E., Marriott, J.J., Jette, N., Pringsheim, T., Makhani, N., Morrow, S.A., Fisk, J.D., Evans, C., Beland, S.G., Kulaga, S., Dykeman, J., Wolfson, C., Koch, M.W., Marrie, R.A., Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol., 13, 2013, 128.
59. Koch, M., Kingwell, E., Rieckmann, P., Tremlett, H., The natural history of primary progressive multiple sclerosis. Neurology 73 (2009), 1996–2002.
60. Krishnan, A.V., Lin, C.S., Park, S.B., Kiernan, M.C., Axonal ion channels from bench to bedside: a translational neuroscience perspective. Prog. Neurobiol. 89 (2009), 288–313.
61. Kuroishi, T., Rios-Avila, L., Pestinger, V., Wijeratne, S.S., Zempleni, J., Biotinylation is a natural, albeit rare, modification of human histones. Mol. Genet. Metab. 104 (2011), 537–545.
62. Lazzarino, G., Amorini, A.M., Eikelenboom, M.J., Killestein, J., Belli, A., Di Pietro, V., Tavazzi, B., Barkhof, F., Polman, C.H., Uitdehaag, B.M., Petzold, A., Cerebrospinal fluid ATP metabolites in multiple sclerosis. Mult. Scler. 16 (2010), 549–554.
63. Leon-Del-Rio, A., Biotin-dependent regulation of gene expression in human cells. J. Nutr. Biochem. 16 (2005), 432–434.
64. Levin, M.C., Douglas, J.N., Meyers, L., Lee, S., Gardner, L.A., Neurodegeneration in multiple sclerosis involves multiple pathogenic mechanisms. Degener. Neurol. Neuromuscul. Dis. 4 (2014), 49–63.
65. LeVine, S.M., Macklin, W.B., Biotin enrichment in oligodendrocytes in the rat brain. Brain Res. 444 (1988), 199–203.
66. Liu, D., Zempleni, J., Holocarboxylase synthetase interacts physically with nuclear receptor co-repressor, histone deacetylase 1 and a novel splicing variant of histone deacetylase 1 to repress repeats. Biochem. J. 461 (2014), 477–486.
67. Lovas, G., Szilagyi, N., Majtenyi, K., Palkovits, M., Komoly, S., Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain 123 (2000), 308–317.
68. Lublin, F.D., Reingold, S.C., Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on clinical trials of new agents in multiple sclerosis. Neurology 46 (1996), 907–911.
69. Luessi, F., Siffrin, V., Zipp, F., Neurodegeneration in multiple sclerosis: novel treatment strategies. Expert. Rev. Neurother. 12 (2012), 1061–1076.
70. Mahad, D.H., Trapp, B.D., Lassmann, H., Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 14 (2015), 183–193.
71. Mahad, D.J., Ziabreva, I., Campbell, G., Lax, N., White, K., Hanson, P.S., Lassmann, H., Turnbull, D.M., Mitochondrial changes within axons in multiple sclerosis. Brain 132 (2009), 1161–1174.
72. Marshall, M.W., Kliman, P.G., Washington, V.A., Mackin, J.F., Weinland, B.T., Effects of biotin on lipids and other constituents of plasma of healthy men and women. Artery 7 (1980), 330–351.
73. Martinelli, B.F., Vacchi, L., Rovaris, M., Capra, R., Comi, G., Mitoxantrone for multiple sclerosis. Cochrane Database Syst. Rev., 5, 2013 CD002127.
74. McGarry, J.D., Takabayashi, Y., Foster, D.W., The role of malonyl-coa in the coordination of fatty acid synthesis and oxidation in isolated rat hepatocytes. J. Biol. Chem. 253 (1978), 8294–8300.
75. McKay, B.E., Molineux, M.L., Turner, R.W., Biotin is endogenously expressed in select regions of the rat central nervous system. J. Comp. Neurol. 473 (2004), 86–96.
76. Mi, S., Hu, B., Hahm, K., Luo, Y., Kam Hui, E.S., Yuan, Q., Wong, W.M., Wang, L., Su, H., Chu, T.H., Guo, J., Zhang, W., So, K.F., Pepinsky, B., Shao, Z., Graff, C., Garber, E., Jung, V., Wu, E.X., Wu, W., LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat. Med. 13 (2007), 1228–1233.
77. Mi, S., Pepinsky, R.B., Cadavid, D., Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic. CNS Drugs 27 (2013), 493–503.
78. Miron, V.E., Kuhlmann, T., Antel, J.P., Cells of the oligodendroglial lineage, myelination, and remyelination. Biochim. Biophys. Acta 1812 (2011), 184–193.
79. Mitsunaga, Y., Ciric, B., Van, K.V., Warrington, A.E., Paz, S.M., Bieber, A.J., Rodriguez, M., Pease, L.R., Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease. FASEB J. 16 (2002), 1325–1327.
80. Mock, D.M., Mock, N.I., Serum concentrations of bisnorbiotin and biotin sulfoxide increase during both acute and chronic biotin supplementation. J. Lab. Clin. Med. 129 (1997), 384–388.
81. Munzel, E.J., Williams, A., Promoting remyelination in multiple sclerosis-recent advances. Drugs 73 (2013), 2017–2029.
82. Narayana, P.A., Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J. Neuroimaging 15 (2005), 46S–57S.
83. Novartis Europharm Ltd, Gilenya (Fingolimod Hydrochloride) Summary of Product Characteristics. 2011 Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002202/human_med_001433.jsp&mid=WC0b01ac058001d124 (accessed 01.12.14.).
84. Olsen, J.A., Akirav, E.M., Remyelination in multiple sclerosis: cellular mechanisms and novel therapeutic approaches. J. Neurosci. Res. 93 (2015), 687–696.
85. Ozand, P.T., Gascon, G.G., Al, E.M., Joshi, S., Al, J.E., Bakheet, S., Al, W.J., Al-Kawi, M.Z., Dabbagh, O., Biotin-responsive basal ganglia disease: a novel entity. Brain 121 (1998), 1267–1279.
86. Pacheco-Alvarez, D., Solorzano-Vargas, R.S., Del Rio, A.L., Biotin in metabolism and its relationship to human disease. Arch. Med. Res. 33 (2002), 439–447.
87. Pacheco-Alvarez, D., Solorzano-Vargas, R.S., Gravel, R.A., Cervantes-Roldan, R., Velazquez, A., Leon-Del-Rio, A., Paradoxical regulation of biotin utilization in brain and liver and implications for inherited multiple carboxylase deficiency. J. Biol. Chem. 279 (2004), 52312–52318.
88. Park, S., Sinko, P.J., The blood-brain barrier sodium-dependent multivitamin transporter: a molecular functional in vitro-in situ correlation. Drug Metab. Dispos. 33 (2005), 1547–1554.
89. Pike, J., Jones, E., Rajagopalan, K., Piercy, J., Anderson, P., Social and economic burden of walking and mobility problems in multiple sclerosis. BMC Neurol., 12, 2012, 94.
90. Podbielska, M., Banik, N.L., Kurowska, E., Hogan, E.L., Myelin recovery in multiple sclerosis: the challenge of remyelination. Brain Sci. 3 (2013), 1282–1324.
91. Polman, C.H., O'Connor, P.W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D.H., Phillips, J.T., Lublin, F.D., Giovannoni, G., Wajgt, A., Toal, M., Lynn, F., Panzara, M.A., Sandrock, A.W., A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354 (2006), 899–910.
92. Polman, C.H., Reingold, S.C., Banwell, B., Clanet, M., Cohen, J.A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., Lublin, F.D., Montalban, X., O'Connor, P., Sandberg-Wollheim, M., Thompson, A.J., Waubant, E., Weinshenker, B., Wolinsky, J.S., Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 69 (2011), 292–302.
93. Prineas, J.W., Barnard, R.O., Kwon, E.E., Sharer, L.R., Cho, E.S., Multiple sclerosis: remyelination of nascent lesions. Ann. Neurol. 33 (1993), 137–151.
94. Rasband, M.N., Trimmer, J.S., Developmental clustering of ion channels at and near the node of Ranvier. Dev. Biol. 236 (2001), 5–16.
95. Rodriguez-Melendez, R., Cano, S., Mendez, S.T., Velazquez, A., Biotin regulates the genetic expression of holocarboxylase synthetase and mitochondrial carboxylases in rats. J. Nutr. 131 (2001), 1909–1913.
96. Romero-Navarro, G., Cabrera-Valladares, G., German, M.S., Matschinsky, F.M., Velazquez, A., Wang, J., Fernandez-Mejia, C., Biotin regulation of pancreatic glucokinase and insulin in primary cultured rat islets and in biotin-deficient rats. Endocrinology 140 (1999), 4595–4600.
97. Said, H.M., Balamurugan, K., Subramanian, V.S., Marchant, J.S., Expression and functional contribution of hTHTR-2 in thiamin absorption in human intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 286 (2004), G491–G498.
98. Salles, J., Sargueil, F., Knoll-Gellida, A., Witters, L.A., Cassagne, C., Garbay, B., Acetyl-CoA carboxylase and SREBP expression during peripheral nervous system myelination. Biochim. Biophys. Acta 1631 (2003), 229–238.
99. Sander, J.E., Packman, S., Townsend, J.J., Brain pyruvate carboxylase and the pathophysiology of biotin-dependent diseases. Neurology 32 (1982), 878–880.
100. Sanofi-Aventis Group, Aubagio Teriflunomide Summary of Product Characteristics. 2013 Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002514/human_med_001645.jsp&mid=WC0b01ac058001d124 (accessed 01.12.14.).
101. Sawamura, H., Fukuwatari, T., Shibata, K., Effects of excess biotin administration on the growth and urinary excretion of water-soluble vitamins in young rats. Biosci. Biotechnol. Biochem. 71 (2007), 2977–2984.
102. Sedel, F., Papeix, C., Bellanger, A., Touitou, V., Lebrun-Frenay, C., Galanaud, D., Gout, O., Lyon-Caen, O., Tourbah, A., High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult. Scler. Relat. Disord. 4 (2015), 159–169.
103. Simpson, S. Jr., Blizzard, L., Otahal, P., Van der Mei, I., Taylor, B., Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J. Neurol. Neurosurg. Psychiatry 82 (2011), 1132–1141.
104. Spector, R., Johanson, C.E., Vitamin transport and homeostasis in mammalian brain: focus on vitamins B and E. J. Neurochem. 103 (2007), 425–438.
105. Spector, R., Mock, D., Biotin transport through the blood-brain barrier. J. Neurochem. 48 (1987), 400–404.
106. Spector, R., Mock, D.M., Biotin transport and metabolism in the central nervous system. Neurochem. Res. 13 (1988), 213–219.
107. Spector, R., Mock, D.M., Biotin transport and metabolism in the central nervous system. Neurochem. Res. 13 (1988), 213–219.
108. Spindler, M., Beal, M.F., Henchcliffe, C., Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatr. Dis. Treat. 5 (2009), 597–610.
109. Stys, P.K., Zamponi, G.W., van, M.J., Geurts, J.J., Will the real multiple sclerosis please stand up?. Nat. Rev. Neurosci. 13 (2012), 507–514.
110. Su, K.G., Banker, G., Bourdette, D., Forte, M., Axonal degeneration in multiple sclerosis: the mitochondrial hypothesis. Curr. Neurol. Neurosci. Rep. 9 (2009), 411–417.
111. Subramanian, V.S., Marchant, J.S., Said, H.M., Biotin-responsive basal ganglia disease-linked mutations inhibit thiamine transport via hTHTR2: biotin is not a substrate for hTHTR2. Am. J. Physiol. Cell Physiol. 291 (2006), C851–C859.
112. Tabarki, B., Al-Shafi, S., Al-Shahwan, S., Azmat, Z., Al-Hashem, A., Al-Adwani, N., Biary, N., Al-Zawahmah, M., Khan, S., Zuccoli, G., Biotin-responsive basal ganglia disease revisited: clinical, radiologic, and genetic findings. Neurology 80 (2013), 261–267.
113. Tansey, F.A., Cammer, W., Acetyl-CoA carboxylase in rat brain. I. Activities in homogenates and isolated fractions. Brain Res. 471 (1988), 123–130.
114. Tansey, F.A., Thampy, K.G., Cammer, W., Acetyl-CoA carboxylase in rat brain. II. Immunocytochemical localization. Brain Res. 471 (1988), 131–138.
115. Tong, L., Structure and function of biotin-dependent carboxylases. Cell. Mol. Life Sci. 70 (2013), 863–891.
116. Tourbah, A., Lebrun-Frenay, C., Edan, G., Clanet, M., Papeix, C., Vukusic, S., De Seze, J., Debouverie, M., Gout, O., Clavelou, P., Defer, G., Laplaud, D., Moreau, T., Labauge, P., Brochet, B., Sedel, F., Pelletier, J., Effect of MD1003 (high doses of biotin) in progressive multiple sclerosis: results of a pivotal phase III randomized double blind placebo controlled study (PL2.002). Neurology, 84, 2015 Presentation PL2.002.
117. Tourbah, A., Lebrun-Frenay, C., Edan, G., Papeix, C., Vukusic, S., De Sèze, J., Debouverie, M., Gout, O., Clavelou, P., Defer, G., Laplaud, D.-A., Moreau, T., Labauge, P., Brochet, B., Sedel, F., Pelletier, J., High-dose Biotin for the Treatment of Progressive Multiple Sclerosis: a Randomised, Double-blind, Placebo-controlled Study. 2015 Submitted.
118. Trapp, B.D., Nave, K.A., Multiple sclerosis: an immune or neurodegenerative disorder?. Annu. Rev. Neurosci. 31 (2008), 247–269.
119. Trapp, B.D., Peterson, J., Ransohoff, R.M., Rudick, R., Mork, S., Bo, L., Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338 (1998), 278–285.
120. Trapp, B.D., Stys, P.K., Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol. 8 (2009), 280–291.
121. Traugott, U., Reinherz, E.L., Raine, C.S., Multiple sclerosis. Distribution of T cells, T cell subsets and Ia-positive macrophages in lesions of different ages. J. Neuroimmunol. 4 (1983), 201–221.
122. Trojano, M., Pellegrini, F., Fuiani, A., Paolicelli, D., Zipoli, V., Zimatore, G.B., Di, M.E., Portaccio, E., Lepore, V., Livrea, P., Amato, M.P., New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann. Neurol. 61 (2007), 300–306.
123. Uchida, Y., Ito, K., Ohtsuki, S., Kubo, Y., Suzuki, T., Terasaki, T., Major involvement of Na(+) -dependent multivitamin transporter (SLC5A6/SMVT) in uptake of biotin and pantothenic acid by human brain capillary endothelial cells. J. Neurochem. 134 (2015), 97–112.
124. Velazquez-Arellano, A., Ortega-Cuellar, D., Hernandez-Mendoza, A., Moreno-Arriola, E., A heuristic model for paradoxical effects of biotin starvation on carbon metabolism genes in the presence of abundant glucose. Mol. Genet. Metab. 102 (2011), 69–77.
125. Wang, H., Pevsner, J., Detection of endogenous biotin in various tissues: novel functions in the hippocampus and implications for its use in avidin-biotin technology. Cell Tissue. Res. 296 (1999), 511–516.
126. Warrington, A.E., Bieber, A.J., Ciric, B., Pease, L.R., Van, K.,V., Rodriguez, M., A recombinant human IgM promotes myelin repair after a single, very low dose. J. Neurosci. Res. 85 (2007), 967–976.
127. Wijeratne, S.S., Camporeale, G., Zempleni, J., K12-biotinylated histone H4 is enriched in telomeric repeats from human lung IMR-90 fibroblasts. J. Nutr. Biochem. 21 (2010), 310–316.
128. Wingerchuk, D.M., Carter, J.L., Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin. Proc. 89 (2014), 225–240.
129. Witte, M.E., Bo, L., Rodenburg, R.J., Belien, J.A., Musters, R., Hazes, T., Wintjes, L.T., Smeitink, J.A., Geurts, J.J., De Vries, H.E., van der valk, P., van, H.J., Enhanced number and activity of mitochondria in multiple sclerosis lesions. J. Pathol. 219 (2009), 193–204.
130. Wolf, B., The neurology of biotinidase deficiency. Mol. Genet. Metab. 104 (2011), 27–34.
131. Wolf, B., Feldman, G.L., The biotin-dependent carboxylase deficiencies. Am. J. Hum. Genet. 34 (1982), 699–716.
132. Young, E.A., Fowler, C.D., Kidd, G.J., Chang, A., Rudick, R., Fisher, E., Trapp, B.D., Imaging correlates of decreased axonal Na+/K+ ATPase in chronic multiple sclerosis lesions. Ann. Neurol. 63 (2008), 428–435.
133. Zawadzka, M., Franklin, R.J., Myelin regeneration in demyelinating disorders: new developments in biology and clinical pathology. Curr. Opin. Neurol. 20 (2007), 294–298.
134. Zempleni, J., Helm, R.M., Mock, D.M., In vivo biotin supplementation at a pharmacologic dose decreases proliferation rates of human peripheral blood mononuclear cells and cytokine release. J. Nutr. 131 (2001), 1479–1484.
135. Zempleni, J., Mock, D.M., Bioavailability of biotin given orally to humans in pharmacologic doses. Am. J. Clin. Nutr. 69 (1999), 504–508.
136. Zempleni, J., Teixeira, D.C., Kuroishi, T., Cordonier, E.L., Baier, S., Biotin requirements for DNA damage prevention. Mutat. Res. 733 (2012), 58–60.
137. Zempleni, J., Wijeratne, S.S., Hassan, Y.I., Biotin. Biofactors 35 (2009), 36–46.
138. Zempleni, J., Wijeratne, S.S., Kuroishi, T., Biotin. Erdman, J.W., MacDonald, I.A., Zeisel, S.H., (eds.) Present Knowledge in Nutrition, 2012, Wiley, John & Sons Inc., Hoboken, NJ, USA, 359–374.
139. Zeng, W.Q., Al-Yamani, E., Acierno, J.S. Jr., Slaugenhaupt, S., Gillis, T., MacDonald, M.E., Ozand, P.T., Gusella, J.F., Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3. Am. J. Hum. Genet. 77 (2005), 16–26.